tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Silber RE et al. | Comparison of the effect of FK 506 and alpha/beta-T-cell antibody R73 on transplant vascular sclerosis after heterotopic rat heart transplantation. | 1998 | Transplant. Proc. | pmid:9636398 |
| Krüger B et al. | Different effects of cyclosporine or tacrolimus on hepatocyte acute phase proteins. | 1998 | Transplant. Proc. | pmid:9636399 |
| McAlister VC | Liposomal tacrolimus: drug migration within blood compartments. | 1998 | Transplant. Proc. | pmid:9636404 |
| Isobe M et al. | Downregulation of endothelin expression in allograft coronary arteries after gene therapy targeting Cdk2 kinase. | 1998 | Transplant. Proc. | pmid:9636407 |
| Fujimura T et al. | Cellular surface molecular and cytokine gene expression in rat heart allografts under optimal doses of cyclosporine and FK 506. | 1998 | Transplant. Proc. | pmid:9636413 |
| Yoshimura N et al. | Development of a macromolecular prodrug of FK 506: III: In vivo disposition of FK 506-dextran conjugate. | 1998 | Transplant. Proc. | pmid:9636415 |
| Yura H et al. | Development of a macromolecular prodrug of FK 506: II: In vitro study for FK 506-dextran conjugate. | 1998 | Transplant. Proc. | pmid:9636416 |
| Chen H et al. | FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. | 1998 | Transplant. Proc. | pmid:9636419 |
| Li S et al. | Intrathymic inoculation of donor bone marrow at the time of transplantation plus a short course of tacrolimus induce long-term acceptance to rat lung allografts. | 1998 | Transplant. Proc. | pmid:9636431 |
| Miki T et al. | Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation. | 1998 | Transplant. Proc. | pmid:9636444 |
| Kobashigawa JA | Controversies in heart and lung transplantation immunosuppression: tacrolimus versus cyclosporine. | 1998 | Transplant. Proc. | pmid:9636445 |
| Rieber J et al. | Effects of tacrolimus and cyclosporine on the coronary microcirculation after heart transplantation: a prospective study with serial intracoronary flow measurements. | 1998 | Transplant. Proc. | pmid:9636446 |
| Undre NA et al. | Pharmacokinetics of tacrolimus (FK506) in primary orthotopic heart transplant patients. | 1998 | Transplant. Proc. | pmid:9636451 |
| Walker RE et al. | Clinical outcomes associated with conversion to tacrolimus-based immunosuppression in pediatric cardiac transplantation. | 1998 | Transplant. Proc. | pmid:9636452 |
| Stempfle HU et al. | Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. | 1998 | Transplant. Proc. | pmid:9636459 |
| Marcus N et al. | Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients. | 1998 | Transplant. Proc. | pmid:9636460 |
| Fritsche L et al. | Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients. | 1998 | Transplant. Proc. | pmid:9636481 |
| Miura S et al. | Effect of tacrolimus on the outcome of renal transplantation with donor-specific blood transfusion. | 1998 | Transplant. Proc. | pmid:9636492 |
| Preston R et al. | FK 506 as primary immunosuppressive therapy in renal transplantation. | 1998 | Transplant. Proc. | pmid:9636493 |
| Jensik SC | Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. | 1998 | Transplant. Proc. | pmid:9636494 |
| Takahashi K et al. | Tacrolimus therapy for ABO-incompatible kidney transplantation. | 1998 | Transplant. Proc. | pmid:9636495 |
| Braun F et al. | Primary low-dose tacrolimus immunosuppressive prophylaxis for high-risk kidney transplant recipients. | 1998 | Transplant. Proc. | pmid:9636496 |
| Tanabe K et al. | Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience. | 1998 | Transplant. Proc. | pmid:9636497 |
| Kinukawa T et al. | Long-term comparison of tacrolimus and cyclosporine-based immunosuppression in kidney recipients with grafts from non-heart-beating cadaver donor. | 1998 | Transplant. Proc. | pmid:9636498 |
| Morris-Stiff G et al. | Preoperative induction with tacrolimus does not have a detrimental effect on primary graft function in adult cadaveric renal transplantation. | 1998 | Transplant. Proc. | pmid:9636499 |
| Eghtesad B et al. | Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics. | 1998 | Transplant. Proc. | pmid:9636500 |
| Turner CD et al. | Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. | 1998 | Transplant. Proc. | pmid:9636501 |
| Carl S et al. | Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept. | 1998 | Transplant. Proc. | pmid:9636502 |
| Budde K et al. | Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. | 1998 | Transplant. Proc. | pmid:9636503 |
| Friemann S et al. | Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. | 1998 | Transplant. Proc. | pmid:9636504 |
| Fernando ON et al. | Elective conversion of patients from cyclosporine to tacrolimus for hypertrichosis. | 1998 | Transplant. Proc. | pmid:9636505 |
| Morris-Stiff G et al. | Conversion from cyclosporine to tacrolimus in renal allograft recipients with chronic graft nephropathy: preliminary report. | 1998 | Transplant. Proc. | pmid:9636506 |
| Busque S et al. | Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. | 1998 | Transplant. Proc. | pmid:9636507 |
| Loss GE et al. | Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. | 1998 | Transplant. Proc. | pmid:9636508 |
| Kliem V et al. | Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients. | 1998 | Transplant. Proc. | pmid:9636509 |
| Copley JB et al. | Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts. | 1998 | Transplant. Proc. | pmid:9636510 |
| Jordan ML et al. | Tacrolimus for rescue of refractory renal allograft rejection. | 1998 | Transplant. Proc. | pmid:9636511 |
| Undre NA and Schäfer A | Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. | 1998 | Transplant. Proc. | pmid:9636512 |
| Manzanares C et al. | Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. | 1998 | Transplant. Proc. | pmid:9636513 |
| van Duijnhoven E et al. | Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. | 1998 | Transplant. Proc. | pmid:9636514 |
| van Duijnhoven E et al. | The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. | 1998 | Transplant. Proc. | pmid:9636515 |
| Christiaans M et al. | Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. | 1998 | Transplant. Proc. | pmid:9636516 |
| Sato S et al. | Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients. | 1998 | Transplant. Proc. | pmid:9636517 |
| Uchida K et al. | Decreasing pancreatic toxicity of tacrolimus by dosage reduction. | 1998 | Transplant. Proc. | pmid:9636518 |
| Rostaing L et al. | Early posttransplantation renal hemodynamics in FK 506-treated kidney recipients with or without prior induction therapy. | 1998 | Transplant. Proc. | pmid:9636519 |
| Rostaing L et al. | Influence of early FK 506 trough levels on glomerular hemodynamics at 3 months in kidney transplant recipients. | 1998 | Transplant. Proc. | pmid:9636520 |
| Morris-Stiff G et al. | Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation. | 1998 | Transplant. Proc. | pmid:9636521 |
| Mendez R | FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group. | 1998 | Transplant. Proc. | pmid:9636522 |
| Vanrenterghem Y et al. | Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. | 1998 | Transplant. Proc. | pmid:9636523 |
| Claesson K et al. | Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. | 1998 | Transplant. Proc. | pmid:9636524 |